Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants.

Autor: Lacy BE; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., Xu Y; AbbVie Inc., North Chicago, Illinois, USA., Taylor DCA; Former employee of Ironwood Pharmaceuticals, Boston, Massachusetts, USA., Kosch KJ; AbbVie Inc., North Chicago, Illinois, USA., Dobrescu R; Acumen Health Research Institute, Ann Arbor, Michigan, USA., Morlock A; Acumen Health Research Institute, Ann Arbor, Michigan, USA., Morlock R; YourCareChoice, Ann Arbor, Michigan, USA., Rooker C; International Foundation for Gastrointestinal Disorders, Milwaukee, Wisconsin, USA.
Jazyk: angličtina
Zdroj: Neurogastroenterology and motility [Neurogastroenterol Motil] 2024 Oct; Vol. 36 (10), pp. e14885. Date of Electronic Publication: 2024 Aug 18.
DOI: 10.1111/nmo.14885
Abstrakt: Background: Chronic idiopathic constipation (CIC) is a disorder of gut-brain interaction characterized by a variety of bowel movement-related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC.
Methods: This study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care-seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported.
Key Results: Two thousand five hundred and thirty-three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over-the-counter medication, while 26.3% were taking neither. In addition, only one-third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all).
Conclusions and Inferences: This study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
(© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: